Akums Drugs and Pharmaceuticals Limited (AKUMS) breaks out, gaining +5% today backed by its Q1 FY27 results showing a 13.9% YoY revenue increase. The stock cleared its 6-month resistance trendline, signaling a bullish breakout. Akums, a mid-cap drug manufacturer specializing in generics, saw its stock move align with strong quarterly performance rather than broader sector momentum.

Technical setup — trendlines & DMA

The current trendline structure shows a 6-month support floor at ₹724, just 1.6% below today’s price, and resistance at ₹728, which the stock has now broken above by 1.1%. The 50-DMA at ₹630.3 is above the 200-DMA at ₹511.6, indicating a positive trend. AKUMS is currently 11% above the 50-DMA, suggesting some extension. Within its 52-week range of ₹409.3 to ₹714.7, the stock is in the upper third, implying that a significant portion of its move is already priced in.

Fundamentals & business context

With a PE of 42.1 and profit margins at 5.9%, AKUMS’s valuation appears stretched relative to its current earnings, especially given its moderate revenue CAGR of 7.0%. However, the strong profit CAGR of 39.1% over 5 years suggests potential for margin expansion. Institutional ownership stands at 13.3%, indicating a cautiously optimistic view from smart money. There is no new NSE catalyst today beyond the Q1 results.

Algorithmic scorecard

The overall score reflects a technically strong but fundamentally mixed profile. Two of the strongest signals are the bullish trend, with the 50-day average above the 200-day average, and the bullish sentiment over the last 30 days, where up days saw nearly double the volume of down days. These indicate systematic accumulation and positive market sentiment. On the weaker side, the low profit margin of 5.9% leaves little room for error, and the negligible dividend yield of 0.15% offers little income for investors, highlighting potential risks.

Company outlook

Management provided forward guidance indicating expected double-digit volume growth in the CDMO business for H1 FY27. The trade generics business is expected to remain stable, while the API business is projected to see reduced losses. The Zambia project is set to commence commercial supplies of $25 million by the end of Q2 FY27, and a European CDMO contract is expected to contribute EUR35 million on a MAT basis starting from the next fiscal. Plans include additional plants getting European GMP approved over the next 18 months, investments in capacity expansion, R&D, and modernization, and expansion of the oral solid facility due to increased volume growth.

Get all details on AKUMS — P&L, peers, shareholding and more on TradeAlone.

Akums Drugs and Pharmaceuticals Limited (AKUMS) announced its consolidated financial results for the quarter ended June 30, 2026, marking a strong start to FY27. The company delivered healthy growth in revenue, operating profitability and PAT, supported by continued momentum in its CDMO business, improved operating performance and healthy customer demand.

Revenue Surge

Akums reported operating revenue of ₹1,167 crore in Q1 FY27, registering a 13.9% year-on-year growth compared with ₹1,024 crore in Q1 FY26. This robust performance was primarily driven by the CDMO business, which saw a significant increase in revenue and EBITDA.

EBITDA and PAT Growth

EBITDA increased 35.4% year-on-year to ₹175 crore, with EBITDA margin improving to 15.0% from 12.6%. PAT stood at ₹101 crore, compared with ₹65 crore in the corresponding quarter last year. PAT margin also improved to 8.4% from 6.2%.

CDMO Business Performance remained the key growth driver during the quarter. CDMO revenue increased to ₹964 crore, compared with ₹813 crore in Q1 FY26, while CDMO EBITDA grew 36.8% year-on-year to ₹163 crore from ₹119 crore in Q1 FY26, supported by continued volume growth and improvement in API prices.

Commenting on the results, Mr. Sanjeev Jain, Managing Director, said, ‘FY27 has begun on a strong and encouraging note. The consistent performance of CDMO showcases healthy demand environment as well as our clients’ trust in Akums as the preferred manufacturing partner.’ Mr. Sandeep Jain, Managing Director, added, ‘We remain focused on strengthening our CDMO leadership, scaling high-value capabilities, and driving operational excellence. Backed by a strong pipeline and prudent capital allocation, we are well-positioned to deliver sustainable growth in the years ahead.’

Source: NSE Corporate Announcement

Fundamental & Technical Analysis of Akums Drugs and Pharmaceuticals Limited

Akums Drugs and Pharmaceuticals Limited belongs to the Healthcare › Drug Manufacturers – Specialty & Generic sector. Here’s a quick read on where the business and the stock stand today.

Akums gains 25.2% over three months and trades near its 52-week highs. Thin margins at 5.9% leave limited room for error — any demand softness or cost spike hits the bottom line hard. Not a single revenue dip or loss quarter in five years — this is a business built to last through cycles. The stock trades at 94% of its 52-week range — near its best levels of the year. Clearly, the market pays a premium for this name. Both the business and the stock move in the right direction. Revenue grows at 7.0%, profits at 39.1%, and the PEG sits at 1.08 — below its growth rate. That combination is rare. Check Fundamentals of Akums Drugs and Pharmaceuticals Limited.

Akums Drugs and Pharmaceuticals Limited (AKUMS) bounced intraday by +5% to ₹698.3 on the NSE, recovering despite a weak 6-month trendline structure. This move can be attributed to the company’s announcement of an upcoming analysts and institutional investor meet, which likely sparked interest and buying activity. In the healthcare sector, specifically within drug manufacturers, AKUMS’s bounce is somewhat company-specific, as the broader sector does not show significant momentum today.

Technical setup — trendlines & DMA

The current 6-month trendline structure for AKUMS shows a breakdown, with the stock trading below both the support and resistance levels. The 6-month support trendline ends at ₹721.2, which is 3.28% above the current price, while the resistance trendline ends at ₹728.07, 4.26% above the current price. The 50-day moving average (DMA) is at ₹622.5, indicating that the stock is trading above this short-term average, while the 200-DMA is at ₹508.6, showing a longer-term upward trend. AKUMS is currently in the upper third of its 52-week range, suggesting that a significant portion of its potential move is already priced in.

Fundamentals & business context

With a PE ratio of 39.7 and profit margins at 5.9%, AKUMS’s valuation appears stretched relative to its current earnings, especially given its moderate revenue CAGR of 7.0%. The market seems to be pricing in potential future growth, possibly driven by the company’s strategic initiatives and expansion plans. Institutional ownership stands at 13.3%, indicating a cautious but present interest from smart money. There was no specific NSE catalyst today beyond the scheduled meet, which likely influenced the intraday bounce.

Algorithmic scorecard

AKUMS’s overall algorithmic scorecard of 82 reflects a technically strong but fundamentally weaker profile. Two of the strongest signals are the bullish trend, with the 50-DMA above the 200-DMA, and the bullish sentiment over the last 30 days, where up days have seen significantly higher volumes than down days. These indicators suggest systematic accumulation and positive market sentiment. However, the company faces risks from its low profit margin of 5.9%, which leaves little room for error, and negligible dividend yield of 0.15%, offering little income to shareholders. Additionally, the stock’s breakdown below support levels indicates underlying weakness that needs to be monitored.

Company outlook

Management provided forward-looking guidance indicating expected double-digit volume growth in the CDMO segment for H1 FY27. The trade generics business is expected to maintain similar revenue and EBITDA levels, while the API business is projected to see reduced losses in FY27. A significant development is the Zambia project, which is expected to commence commercial supplies of $25 million by the end of Q2 FY27. Additionally, a European CDMO contract is anticipated to contribute EUR35 million on a moving annual total (MAT) basis starting from the next fiscal. The company plans to invest in capacity expansion, R&D, and modernization, with additional plants expected to receive European GMP approval over the next 18 months. The expansion of the oral solid facility is also underway due to increased volume growth.

Get all details on AKUMS — P&L, peers, shareholding and more on TradeAlone.